



RECEIVED
76168
SEP 24 2003

TECH CENTER 1600/2900

Approved for use through 08/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/098,834
	Filing Date	March 15, 2002
	First Named Inventor	Ganem, et al.
	Art Unit	1616
	Examiner Name	QAZI, S.
Total Number of Pages in This Submission	Attorney Docket Number	10845-139

RECEIVED
SEP 24 2003
TECH CENTER 1600/2900

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Technology Center (TC)
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Post Card
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Stephen J. Gaudet Reg. No.: 48,921
Signature	
Date	9/18/03

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.	
Typed or printed name	Renee P. Granito
Signature	
Date	9/18/03

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
SEP 24 2003
TECH CENTER 1600/2900

Applicant: Ganem *et al.*)
)
Serial No.: 10/098,834)
)
Filed: March 15, 2002)
)
Title: Enone Cancer Therapeutics)
)
Docket No.: 10845-139)
)
)
)

Art Unit: 1616
Examiner: Qazi, S.


RECEIVED
SEP 24 2003
TECH CENTER 1600/2900

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING (37.C.F.R. 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Box Non-Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date set forth below.

9/18/03
date of mail deposit

By: 
Stephen J. Gaudet
Reg. No. 48,921
Attorney for Applicants

REPLY TO RESTRICTION REQUIREMENT

Sir:

In response to a Restriction Requirement dated August 22, 2003, Applicants file the following reply.

Pursuant to 35 USC § 121 Applicants Required to Elect a Single Species

The Examiner contends that the present application [*sic*] "contains claims 1-47 directed to the following patentably distinct species of the claimed invention: Contain numerous, composition and methods of treating cancer having different class of enone compounds ... and therapeutically active steroid derivatives of sex hormones ..."

Applicants strongly disagree with this restriction requirement. However, Applicants understand that upon receiving a restriction requirement an election must be made in order to proceed with prosecution. Therefore, Applicants elect with traverse, the compound COMC 7 where X is oxygen and R is testosterone. For example, the Examiner is directed to claim 1 where COMC 7 is labeled "7" and X is oxygen and R is testosterone. This is a single species and complies with the Examiner's demand.

Applicants assert that the claimed invention comprises one distinct invention. Enones are well recognized class of organic compounds. They have a specific structure and chemistry. It is not proper to restrict a single invention. As MPEP § 806.05 states:


Where two or more related inventions are being claimed, the principle question to be determined in connection with a requirement to restrict or a rejection on the ground of double patenting is whether or not the inventions as claimed are distinct. If they are distinct, restriction may be proper. If they are not distinct, restriction is NEVER proper. [underline and emphasis added]

The presently claimed invention is directed toward enone compounds that can be used in cancer therapeutics. Applicants assert that the claimed invention requires an examiner to perform a single search, a search directed toward enones and cancer therapeutics. Hence, a restriction is unwarranted.

Applicants respectfully request reconsideration and withdrawal of this restriction requirement.

The Examiner is invited to call the undersigned attorney at (617) 854-4237 should he determine that a telephonic interview would expedite prosecution of this case.

Respectfully submitted,



Stephen A. Gaudet, Ph.D.
Attorney for Applicant
Reg. No. 48,921

Date:

9/18/03